研究单位：[1]Dongzhimen Hospital, Beijing[2]Beijing Tiantan Hospital[3]Beijing Chao Yang Hospital[4]Guangdong Provincial Hospital of Traditional Chinese Medicine[5]The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine[6]Beijing Emergency Medical Center[7]The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine[8]Deyang People's Hospital[9]The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine[10]The Second Hospital of Hebei Medical University[11]The First Affiliated Hospital of Henan University of Traditional Chinese Medicine[12]Hunan Academy of Chinese Medicine[13]The First Hospital of Jilin University[14]China-Japan Union Hospital, Jilin University[15]Jiangmen Wuyi Hospital of Traditional Chinese Medicine[16]Jiangxi Provincial People's Hopital[17]Mianyang Central Hospital[18]The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School[19]Shandong University of Traditional Chinese Medicine[20]Shaanxi Provincial People's Hospital[21]Shaanxi Provincial Hospital of Traditional Chinese Medicine[22]The Affiliated Hospital of Shaanxi University of Chinese Medicine[23]Tianshui Hospital of Traditional Chinese Medicine[24]Wuxi Hospital of Traditional Chinese Medicine[25]The First Hospital of Wuhan[26]Zhejiang Provincial Tongde Hospital[27]Zhejiang Provincial Hospital of TCM[28]Zhongshan Hospital Of Traditional Chinese Medicine[29]The Fifth People Hospital of Chongqing[30]Chongqing Traditional Chinese Medicine Hospital[31]Zibo Hospital of Traditional Chinese Medicine[32]Liling Hospital of Traditional Chinese Medicine[33]Cangzhou Hospital of Integrated Medicine[34]Yantai Yuhuangding Hospital
The main purpose of this trial is to determine whether Xingnaojing, intravenously administered within 24 hours of symptom onset, improves the 3-month outcome in participants with acute ischemic stroke.
